Literature DB >> 22740943

Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.

Akira Takakura1, Akinobu Kurita, Takashi Asahara, Masanori Yokoba, Michiko Yamamoto, Shinichiro Ryuge, Satoshi Igawa, Yukitoshi Yasuzawa, Jiichiro Sasaki, Hirosuke Kobayashi, Noriyuki Masuda.   

Abstract

One of the dose-limiting toxicities of irinotecan hydrochloride (CPT-11) is delayed-onset diarrhea. CPT-11 is converted to its active metabolite, SN-38, which is conjugated to SN-38 glucuronide (SN-38G). SN-38G excreted in the intestinal lumen is extensively deconjugated by bacterial β-glucuronidase, resulting in the regeneration of SN-38, which causes diarrhea. However, the deconjugation of SN-38G by the intestinal microflora remains to be clarified. This study aimed to investigate the microbial transformation of SN-38G by an anaerobic mixed culture of rat cecal microorganisms. Concentrations of SN-38G and SN-38 were then determined using high-performance liquid chromatography. Complete deconjugation of SN-38G to SN-38 in the mixed cultures was observed within 1 h of incubation, with 62.7% of the added SN-38G being found in the supernatant. Approximately 80.4% of the SN-38 in the supernatant was bound to protein, and the remaining 19.6% was detected as active free SN-38. In total, only 12.3% (19.6 × 62.7%) of the SN-38G added to the test tube was found in the supernatant in the ultrafiltrable free form, indicating that approximately 90% of the SN-38G added to the growth medium either remained adsorbed onto the pelleted fraction or occurred in a protein-bound form in the supernatant. The remaining 10% of the SN-38G added to the growth medium existed in the unbound form, the form capable of causing damage to the intestinal membrane. In conclusion, these results indicated that the greater part of the SN-38 produced from SN-38G by the action of bacterial β-glucuronidase is rapidly adsorbed onto intestinal bacterial cell walls or dietary fibers in pelleted fraction, and only 10% remains in the ultrafiltrable unbound form in the intestinal luminal fluid.

Entities:  

Year:  2011        PMID: 22740943      PMCID: PMC3362476          DOI: 10.3892/ol.2011.519

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

1.  Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.

Authors:  K Takasuna; T Hagiwara; K Watanabe; S Onose; S Yoshida; E Kumazawa; E Nagai; T Kamataki
Journal:  Cancer Chemother Pharmacol       Date:  2006-01-25       Impact factor: 3.333

2.  High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.

Authors:  A Kurita; N Kaneda
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-03-19

3.  Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.

Authors:  B H Lenfers; T M Loeffler; C M Droege; T U Hausamen
Journal:  Ann Oncol       Date:  1999-10       Impact factor: 32.976

4.  Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.

Authors:  Y Takeda; K Kobayashi; Y Akiyama; T Soma; S Handa; S Kudoh; K Kudo
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

Review 5.  Irinotecan (CPT-11): pharmacology and clinical applications.

Authors:  N Masuda; S Kudoh; M Fukuoka
Journal:  Crit Rev Oncol Hematol       Date:  1996-09       Impact factor: 6.312

6.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

Authors:  D M Savarese; S Halabi; V Hars; W L Akerley; M E Taplin; P A Godley; A Hussain; E J Small; N J Vogelzang
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

Review 7.  Gastrointestinal toxicity or irinotecan.

Authors:  J R Hecht
Journal:  Oncology (Williston Park)       Date:  1998-08       Impact factor: 2.990

8.  Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.

Authors:  Michiko Yamamoto; Akinobu Kurita; Takashi Asahara; Akira Takakura; Ken Katono; Maiko Iwasaki; Shinichiro Ryuge; Mayuko Wada; Sayaka Onoda; Tomoko Yanaihara; Masanori Yokoba; Hisashi Mitsufuji; Yasuto Nishii; Tomoya Fukui; Noriyuki Masuda
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

9.  Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.

Authors:  L P Rivory; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

View more
  4 in total

1.  Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.

Authors:  Hiro Takahashi; Kimie Sai; Yoshiro Saito; Nahoko Kaniwa; Yasuhiro Matsumura; Tetsuya Hamaguchi; Yasuhiro Shimada; Atsushi Ohtsu; Takayuki Yoshino; Toshihiko Doi; Haruhiro Okuda; Risa Ichinohe; Anna Takahashi; Ayano Doi; Yoko Odaka; Misuzu Okuyama; Nagahiro Saijo; Jun-ichi Sawada; Hiromi Sakamoto; Teruhiko Yoshida
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

2.  Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats.

Authors:  Chao Deng; Bo Deng; Liqun Jia; Huangying Tan; Pan Zhang; Sida Liu; Yanan Zhang; Aiping Song; Lin Pan
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-12       Impact factor: 2.629

3.  GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy.

Authors:  Congcong Lin; Fan Tong; Rui Liu; Rou Xie; Ting Lei; Yuxiu Chen; Zhihang Yang; Huile Gao; Xiangrong Yu
Journal:  Acta Pharm Sin B       Date:  2020-10-15       Impact factor: 11.413

4.  Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.

Authors:  Ana Lucić Vrdoljak; Nino Fuchs; Anja Mikolić; Suzana Žunec; Irena Brčić Karačonji; Andreja Jurič; Ljerka Prester; Vedran Micek; Marijana Neuberg; Samir Čanović; Gordan Mršić; Nevenka Kopjar
Journal:  Molecules       Date:  2018-06-01       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.